Abstract
PREVIEWSince 2000, a new pneumococcal conjugate vaccine has been on the US market, offering immunization against seven serotypes. Its use has the potential to dramatically reduce the incidence of pneumococcal disease and its sequelae in children. Here, the authors review the efficacy, safety, and cost of the new pneumococcal vaccine and offer guidelines on how to incorporate this newer vaccine into today's immunization regimens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
